Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CSP #403 - Trial of Varicella Zoster Vaccine for the Prevention of Herpes Zoster and Its Complications
Brief Summary: The incidence and severity of HZ (or shingles), as well as the frequency and severity of its complications, increases markedly with increasing age. More than half of all cases occur in persons over the age of 60. Even without complications, HZ can interfere with an elderly patient's ability to perform essential activities of daily living, resulting in a loss of independence that is emotionally devastating and frequently irreversible. The most common complication of HZ in elderly persons is postherpetic neuralgia (PHN), which frequently results in disordered sleep, chronic fatigue, anxiety and severe depression. Antiviral therapy has a modest impact on the acute phase of HZ. However, it does not appear to prevent the development of PHN.

This study is a 5.5 year randomized, double-blind, placebo-controlled, efficacy trial to determine whether vaccination with live-attenuated Oka/Merck varicella-zoster decreases the incidence and/or severity of herpes zoster (HZ) and its complications in adults 60 years of age and older.


Options:
A: Arm Label: GSK1437173A _LD Group; Type: EXPERIMENTAL; Interventions: Biological: Herpes Zoster vaccine GSK1437173A Low Dose | Arm Label: GSK1437173A _MD Group; Type: EXPERIMENTAL; Interventions: Biological: Herpes Zoster vaccine GSK1437173A Medium Dose | Arm Label: GSK1437173A _HD Group; Type: EXPERIMENTAL; Interventions: Biological: Herpes Zoster vaccine GSK1437173A High Dose | Arm Label: Placebo + GSK1437173A _HD Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Herpes Zoster vaccine GSK1437173A High Dose, Biological: Placebo | Arm Label: GSK1437173A_MODIFIED GROUP; Type: ACTIVE_COMPARATOR; Interventions: Biological: Herpes Zoster vaccine GSK1437173A Modified | Intervention Type: BIOLOGICAL; Name: Herpes Zoster vaccine GSK1437173A Low Dose; Assigned to Arm(s): GSK1437173A _LD Group | Intervention Type: BIOLOGICAL; Name: Herpes Zoster vaccine GSK1437173A Medium Dose; Assigned to Arm(s): GSK1437173A _MD Group | Intervention Type: BIOLOGICAL; Name: Herpes Zoster vaccine GSK1437173A High Dose; Assigned to Arm(s): GSK1437173A _HD Group, Placebo + GSK1437173A _HD Group | Intervention Type: BIOLOGICAL; Name: Herpes Zoster vaccine GSK1437173A Modified; Assigned to Arm(s): GSK1437173A_MODIFIED GROUP | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo + GSK1437173A _HD Group
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Biological: Varicella-zoster vaccine | Arm Label: Arm 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Varicella-zoster vaccine; Assigned to Arm(s): Arm 1 | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Arm 2
C: Arm Label: GSK1437173A 18-30 Years Old Group; Type: EXPERIMENTAL; Interventions: Procedure: Blood sampling for assay of persistence of immunogenicity | Arm Label: GSK1437173A 50-70 Years Old Group; Type: EXPERIMENTAL; Interventions: Procedure: Blood sampling for assay of persistence of immunogenicity | Intervention Type: PROCEDURE; Name: Blood sampling for assay of persistence of immunogenicity; Assigned to Arm(s): GSK1437173A 18-30 Years Old Group, GSK1437173A 50-70 Years Old Group
D: Arm Label: Single Dose of Zostavax; Type: EXPERIMENTAL; Interventions: Biological: Zostavax | Arm Label: Zostavax - Day 0 and Month 1; Type: EXPERIMENTAL; Interventions: Biological: Zostavax | Arm Label: Zostavax - Day 0 and Month 3; Type: EXPERIMENTAL; Interventions: Biological: Zostavax | Intervention Type: BIOLOGICAL; Name: Zostavax; Assigned to Arm(s): Single Dose of Zostavax, Zostavax - Day 0 and Month 1, Zostavax - Day 0 and Month 3

Answer: B